GLAXOSMITH Glaxosmithkline Bangladesh Ltd.
Pharmaceuticals & Chemicals
Tk 2,046.8 as of 2025-04-30 15:01:34
Rank 321 of all scored
Data completeness 40%
Data completeness 40%
Override: Avoid. Operational status: N/A.
Limited data for this company (40% of inputs available): treat the score with caution.
Score breakdown
Consistency —
Profitability —
Solvency —
Valuation 10
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Concerns
- Valuation P/E 25.01 is high (above 20)
- Valuation Trades at 17.47x book value (NAV Tk 117.19, price Tk 2046.8)
- Valuation Price is 341% above the Graham fair value (Tk 464.5)
Risk flags
- Sponsors hold 90.51%: very little free float
- Within 0.02% of its 52-week low: check WHY before treating it as cheap
- Free float only 9.49%
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
0% above the low, 0.3% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 90.5%
- Institution 5.5%
- Foreign 0.4%
- Public 3.6%
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap n/a, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.